Search PubMed⌕ Search

Biomedical subjects

B Hoerni

Publications and source records attributed to B Hoerni.

At least 19 recordsLinked to original sources

[Stethoscope].

Explore the source record for details and available documents.

Humans↗

[Janus].

Explore the source record for details and available documents.

Clinical Medicine↗

[Hair].

Explore the source record for details and available documents.

Alopecia↗

[Maieutics].

Explore the source record for details and available documents.

Clinical Medicine↗

[Stochastic].

Explore the source record for details and available documents.

Animals↗

[Humor].

Explore the source record for details and available documents.

Delivery of Health Care↗

[Cancer information and media: ethical and deontological aspect].

Public information in medicine - including oncology - is not new and is growing with the development of the media. The majority is news preferably spectacular for the entertainment of the reader or viewer; there are some reviews and also educative papers or programs in specialized journals. Often this information is given or sponsored by private interests which are not always clear and which do not always have public interest in mind. All medical information may be easily accessible, especially if it is useful for the people concerned. It must be independent, genuine, clear. Physicians may play an important role in health education for the general public and for special patients. They have to give proved data, in an understandable form, with caution, keeping in mind the interest of informed persons.

Ethics, Medical↗

Semen analysis and cryoconservation before treatment in Hodgkin's disease.

BACKGROUND: The prophylaxis of the late effects of chemotherapy and radiotherapy has become one of the major concerns in the management of Hodgkin's disease (HD). Unlike other complications, male sterility could be managed by prior semen preservation (SP). PATIENTS AND METHODS: To evaluate the semen quality of patients with HD and the outcome of insemination, we reviewed spermograms of patients who underwent SP before any treatment. The following criteria were necessary: 1) age > 16 and < 50; 2) HD of any stage; 3) informed about male sterility after HD treatment; 4) fully consenting. RESULTS: Such a proposal was made to 316 men, and 94 fulfilled the criteria. All patients underwent an initial chemotherapy. Mean age of the cohort was 27.5 years (range 16-48 years). Pretherapeutic staging of HD revealed 38 stage I (40%), 38 II (38%), 14 III (15%) and 4 IV (4%). Semen analysis before cryoconservation showed an overall 53% of normal or subnormal cases (50 cases). The analysis of semen quality and spermatozoid amount according to various parameters failed to find a correlation with stage, B symptoms, age, or biologic data (LDH, WBC, platelets, ESR). The use of cryopreserved semen was requested by 13 patients; 88 inseminations were performed leading to 9 pregnancies and 2 births. CONCLUSIONS: The low rate of success with cryopreserved semen in these cases suggests the need for a more careful design of non-toxic chemotherapy regimens in combined modality treatment.

Adolescent↗

Competitive polymerase chain reaction to quantify tumor cells in peripheral blood of patients with T(14;18)-bearing follicular non-Hodgkin's lymphoma: an exploratory study in 8 patients.

Detection of residual disease in follicular lymphoma is hampered by the observation of t(14;18)-bearing cells in the blood of healthy adult humans. To overcome this problem, we decided to validate a quantification method of t(14;18)-bearing cells and test it in t(14;18)-bearing follicular lymphomas (FL). We designed a competitive PCR method to quantify t(14;18)-bearing cells in peripheral blood. First, we controlled overall reliability (specificity, sensitivity, reproducibility, precision and accuracy); then we used our method to study 16 peripheral blood samples collected in 8 patients with t(14;18)-bearing FL. There were considerable variations in the number of circulating tumor cell (CTC) in FL patients, ranging from zero to 17,813 cells/ml. In 2 patients who were sampled before and after treatment and who attained complete remission (CR), a significant decrease in the number of CTC was observed. In 3 patients with detectable CTC during CR, relapse occurred 4 to 11 months later. Of 3 patients with no detectable CTC, 2 remain in CR 35 and 95 months later, but one relapsed 11 months after sample collection. These preliminary results suggest that quantification of CTC may be worthwhile in follicular lymphoma. It may improve our ability to predict relapse occurrence, but also may help in understanding this peculiar disease. Int. J. Cancer (Pred. Oncol.) 84:558-561, 1999.

Chromosomes, Human, Pair 14↗